PDS Biotechnology Corporation (PDSB)

PDS Biotechnology Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Selling, General & Admin	15.1	15.28	12.24	10.18	6.98	10.98
Research & Development	28.62	27.76	29.43	11.25	7.92	6.1
Other Operating Expenses	0	0	0	0	0	3.95
Operating Expenses	43.72	43.05	41.67	21.44	14.9	21.03
Operating Income	-43.72	-43.05	-41.67	-21.44	-14.9	-21.03
Interest Expense / Income	1.57	1.3	0.38	-0	0	0.03
Other Expense / Income	-	-	-	-	-0.06	-13.69
Pretax Income	-45.29	-44.35	-42.05	-21.43	-14.85	-7.38
Income Tax	-1.41	-1.41	-1.2	-4.52	0	-0.38
Net Income	-43.89	-42.94	-40.85	-16.92	-14.85	-7
Shares Outstanding (Basic)	35	31	29	26	17	5
Shares Outstanding (Diluted)	35	31	29	26	17	5
Shares Change	14.42%	8.23%	11.73%	52.86%	243.98%	45.87%
EPS (Basic)	-1.37	-1.39	-1.43	-0.66	-0.89	-1.44
EPS (Diluted)	-1.37	-1.39	-1.43	-0.66	-0.89	-1.44
Free Cash Flow	-30.39	-33.64	-25.71	-12.49	-13.15	-17.8
Free Cash Flow Per Share	-0.87	-1.09	-0.90	-0.49	-0.79	-3.66
EBITDA	-43.6	-42.87	-41.43	-21.19	-14.67	-7.25
Depreciation & Amortization	0.12	0.18	0.24	0.25	0.18	0.1
EBIT	-43.72	-43.05	-41.67	-21.44	-14.85	-7.35

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).